Navigation Links
Omnicare Clinical Research Licenses LiquentConnect to Create Added Value for Clients
Date:1/26/2010

PHILADELPHIA, Jan. 26 /PRNewswire/ -- Liquent, Inc. today announced Omnicare Clinical Research has licensed LiquentConnect® - a hosted software as a service (SaaS) solution used to quickly and easily create, review, amend and submit regulatory dossiers.  Omnicare Clinical Research is a leading Phase I to IV global contract research organization serving the biopharmaceutical and medical device industries.

LiquentConnect enables organizations to produce their own eCTD and non electronic submissions without investing in IT infrastructure.  All software and hardware upgrades are managed and executed by Liquent.  LiquentConnect is fully executable for eCTD, NeeS and CTD publishing.  

"As portions of the industry shift toward SaaS, we are pleased to offer LiquentConnect, a SaaS solution publishing tool," said Rick Riegel, Liquent's Chief Executive Officer. "Liquent is committed to providing value-add solutions to our customers.  LiquentConnect provides reliable, secure access to your dossiers from anywhere with an internet connection."

Omnicare Clinical Research selected Liquent and will be utilizing LiquentConnect as its hosted solution provider due to Liquent's depth of expertise within the regulatory and life-sciences industry.  The benefits of implementing a fully-managed SaaS solution outweighed the time and resource investment required for other solutions.  

"LiquentConnect provides our organization and our customers with project submission data that is safe and secure.  Liquent provided us with a solution that is not only flexible, but one that we believe can expand to meet our needs and offer an efficient and cost-effective tool to address a variety of situations, from eCTD to NeeS to paper,"
'/>"/>

SOURCE Liquent, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
2. Steven Leventer Joins PharmaNet Development Group as Vice President, Clinical Research Neuroscience
3. Clinical Data Presented at Asia PCR/Sing LIVE Demonstrate Benefits of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) in Challenging Patient Subsets
4. Michael J. Fox Foundation Awards $2.1 Million to Drive Six Industry Teams Pre-Clinical Development of Neuroprotective Parkinsons Therapies
5. Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
6. ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers
7. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
8. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
9. Enbrel Will Remain Decision Resources Clinical Gold Standard Through 2018 for the Treatment of Rheumatoid Arthritis
10. PharmaNet Development Group Symposia Crossing the Bridge from Preclinical to Clinical Studies to be Held February 2010 in Basel, Dusseldorf and Vienna
11. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015  Amgen (NASDAQ: AMGN ) ... the areas of Alzheimer,s disease and migraine. The ... by teaming up with Novartis on a differentiated ... genetically predisposed individuals at risk of developing Alzheimer,s ... the commercialization of its migraine programs in the ...
(Date:9/1/2015)... PARK, Calif. , Sept. 1, 2015 ... device company that is providing innovative evidence-based solutions for ... company has submitted its preliminary response to the Patent ... petitions for inter partes review (IPR), filed by ... of certain claims in U.S. Patent No. 8,359,102 (the ...
(Date:9/1/2015)... Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) today ... evaluating effect of RomosozUmab Compared with Teriparatide in ... fracture pReviously treated with bisphosphonatE therapy). The study ... significant difference in favor of romosozumab in the ...
Breaking Medicine Technology:Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 2Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 3Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 4Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 5Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 6Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 7Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 8Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 9Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9
(Date:9/1/2015)... Diego, CA (PRWEB) , ... September 01, 2015 , ... ... Bellus Academy will present “The Beauty Behind the Fashion” on Thursday, Oct. 1, ... Diego® (FWSD), will shine the spotlight on the collaboration between fashion and professional hair, ...
(Date:9/1/2015)... (PRWEB) , ... September 01, ... ... seeking better therapeutic options to efficiently cure and prevent different malignancies. Some ... cancers have different pathophysiological properties due to which distinctive approach is necessary ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... Vendor “Hair Extension Vending Machine,” is still strongly maintaining her firm’s success in ... and beauty tools. In her upcoming city-to-city tour, Ellis will be providing “Look ...
(Date:9/1/2015)... ... 2015 , ... PetPace, the provider of an innovative IoT ... today announced its integration with leading veterinary Practice Management Software vendor Cornerstone. ... Management Software packages in the US. Practice Management Software helps veterinarians manage every ...
(Date:9/1/2015)... ... September 01, 2015 , ... Zecurion, a leading developer of data loss prevention ... of endpoint DLP developed specifically for Mac OS. , In June 2015, the company ... and information security professionals had participated. The beta test done by the developer community ...
Breaking Medicine News(10 mins):Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Zecurion Announces Endpoint Security for Mac 2
... , THURSDAY, Aug.5 (HealthDay News) -- During an attack ... girl,s skull, almost killing her. U.S. military helicopter ... where a U.S. neurosurgeon operated, saving her life. ... injured U.S. servicemen and women. But when they have ...
... to find, here,s good news for the under-qualified: A ... ( http://www.fasebj.org ) shows that being a highly cited ... on leading management positions at research institutions. This study ... exist at research institutions where top-cited scientists either do ...
... are the most common injury for both urban and rural ... injuries in people 65 and older, according to a new ... School of Public Health,s Center for Injury Research and Policy. ... of non-fatal injuries among older adults in China, who make ...
... The first for-profit insurance company approved to offer ... restricted access to primary care, according to data ... Journal of Medicine . Researchers say the findings ... health law, which is modeled after the Massachusetts ...
... HealthDay Reporter , WEDNESDAY, Aug. 4 (HealthDay News) ... are tied to recurrent, aggressive breast cancers, new research suggests. ... cells, may someday help doctors better predict which breast cancers ... say. "We had a hint that iron might ...
... 4, 2010 The Harold C. Simmons Comprehensive Cancer ... Cancer Institute (NCI) designation, an elite distinction held by ... Cancer Center is the first medical center in North ... bestows upon the nation,s top cancer centers in recognition ...
Cached Medicine News:Health News:U.S. Military Surgeons Saving Children's Lives in Afghanistan 2Health News:U.S. Military Surgeons Saving Children's Lives in Afghanistan 3Health News:Help wanted: Highly cited researchers needed for high-ranking positions at research institutions 2Health News:Falls the leading cause of injury among older adults in China 2Health News:Doctors hard to find for patients in Massachusetts' first for-profit health plan 2Health News:Doctors hard to find for patients in Massachusetts' first for-profit health plan 3Health News:A New Marker to Spot Aggressive Breast Cancers? 2Health News:UT Southwestern's cancer center earns National Cancer Institute designation 2Health News:UT Southwestern's cancer center earns National Cancer Institute designation 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: